Diagnostic potential of plasma CD30(+) small extracellular vesicles in Hodgkin lymphoma

Cover Page

Cite item

Full Text

Abstract

Background. In current clinical practice, there are no reliable methods to stratify patients with a high risk of relapse or with a primary refractory form of Hodgkin lymphoma. Quantification of CD30-positive small extracellular vesicles (CD30(+)SEV) in plasma seems to be a possible approach to solve this issue. CD30(+)SEV can be quantified by the AuNP aptasensor technology based on the enzyme-mimetic properties of gold nanoparticles and the CD30-specific affinity of DNA aptamers.

Aim. To quantify CD30(+)SEV in the plasma of patients with newly diagnosed Hodgkin lymphoma; to investigate the links between estimated parameter and clinical/morphological properties of disease and the effect of first two chemotherapy cycles.

Material and methods. A semi-quantitative analysis of CD30(+)SEV in the plasma of patients with Hodgkin lymphoma (n = 55) was performed using the AuNP aptasensor. The relationship between the CD30(+)SEV concentration and the data of standard diagnostic approaches was evaluated through the r-Pearson correlation coefficient, the Mann–Whitney and Kruskal–Wallis criteria.

Results. The plasma concentration of CD30(+)SEV in patients with Hodgkin lymphoma correlates with the quantity of CD30(+) cells in tissues of biopsied lymph nodes (r = 0.8) and the total lesion glycolysis estimated by PET/CT (r = 0.9). Patients with a relatively high concentration of CD30(+)SEV are characterized by an increase of erythrocyte sedimentation rate and leukocytosis compared with patients with a lower concentration of CD30(+)SEV. Two cycles of chemotherapy reduced CD30(+)SEV concentration, and this effect was more pronounced in patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regime than the BEACOPPesc (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisolone, procarbazine).

Conclusion. AuNP-aptasensor can be used for semi-quantitative assessment of CD30(+)SEV in plasma. The estimated CD30(+)SEV concentration correlates with the clinical and morphological parameters of patients with Hodgkin lymphoma and may reflect the severity of the disease. To assess the diagnostic and/or prognostic potential of developed technology, large-scale multicenter studies are required.

About the authors

K. E. Katsuba

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-7373-5206

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

L. A. Kramynin

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-4542-8353

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

M. A. Slyusarenko

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-3677-1558

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

A. V. Shalaev

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-6148-6994

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

V. V. Sharoyko

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-3717-0471

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

A. A. Valitova

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-1279-4667

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

A. S. Artem’eva

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-2948-397X

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

P. I. Krzhivitskiy

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-6864-6348

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

L. V. Filatova

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-0728-4582

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

A. V. Malek

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: anastasia@malek.com.ru
ORCID iD: 0000-0001-5334-7292

Anastasiya V. Malek 

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

References

  1. Weniger M.A., Küppers R. Molecular biology of Hodgkin lymphoma. Leukemia 2021;35(4):968–81. doi: 10.1038/s41375-021-01204-6
  2. Santisteban-Espejo A., Bernal-Florindo I., Perez-Requena J. et al. The Need for standardization in next-generation sequencing studies for classic Hodgkin lymphoma: a systematic review. Diagnostics 2022;12(4):963. doi: 10.3390/diagnostics12040963
  3. Aoki T., Chong L.C., Takata K. et al. Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma. Cancer Discov 2020;10(3):406–21. doi: 10.1158/2159-8290.CD-19-0680
  4. De Kanter J.K., Margaritis T., Beishuizen A. et al. Single-cell RNA sequencing reveals that childhood classical Hodgkin Lymphoma resembles normal inflammation except for T cell exhaustion. Blood Cancer Discov 2022;3:Abstract A37. doi: 10.1158/2643-3249.LYMPHOMA22-A37
  5. Shi Y.K., Tao X.H., He Y. et al. Survival and prognosis analysis of patients with Hodgkin lymphoma treated with standard treatment paradigm. Zhonghua Yi Xue Za Zhi 2022;102(41):3295–303. doi: 10.3760/cma.j.cn112137-20220420-00864
  6. Merabishvili M.V. Survival of cancer patients. Issue 2. Volume I. Saint Petersburg, 2011. (In Russ.).
  7. Mamedova A.A., Mochkin N.E., Sarzhevskiy V.O. et al. Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin’s lymphoma as a 2nd line treatment before autologous hematopoietic stem cell transplantation (preliminary results). Onkogematologiya = Oncohematology 2022;17(3):40–7. (In Russ.). doi: 10.17650/1818-8346-2022-17-3-40-47
  8. Savino F.D., Rigali F., Giustini V. et al. Liquid biopsy in cancer: focus on lymphoproliferative disorders. Cancers (Basel) 2022;14(21):5378. doi: 10.3390/cancers14215378
  9. Alcoceba M., García‐Álvarez M., Chillón M.C. et al. Liquid biopsy: a non‐invasive approach for Hodgkin lymphoma genotyping. Br J Haematol 2021;195(4):542–51. doi: 10.1111/bjh.17719
  10. Repetto O., Lovisa F., Elia C. et al. Proteomic exploration of plasma exosomes and other small extracellular vesicles in pediatric Hodgkin lymphoma: a potential source of biomarkers for relapse occurrence. Diagnostics 2021;11(6):917. doi: 10.3390/diagnostics11060917
  11. Slyusarenko M., Shalaev S., Valitova A. et al. AuNP Aptasensor for Hodgkin lymphoma monitoring. Biosensors 2022;12(1):23. doi: 10.3390/bios12010023
  12. Boellaard R., O’Doherty M.J., Weber W.A. et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37(1):181–200. doi: 10.1007/s00259-009-1297-4
  13. Slyusarenko M., Nikiforova N., Sidina E. et al. Formation and evaluation of a two-phase polymer system in human plasma as a method for extracellular nanovesicle isolation. Polymers (Basel) 2021;13(3):458. doi: 10.3390/polym13030458
  14. Slyusarenko M.A., Sidina E.I., Nazarova I.V. et al. Method for isolation of exosomes from blood plasma. Patent RU 2 741 776 C1. 2021. (In Russ.).
  15. Hansen H.P., Trad A., Dams M. et al. CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligandexpressing bystander cells with Brentuximab-Vedotin, in vitro. Oncotarget 2016;7(21):30523–5. doi: 10.18632/oncotarget.8864
  16. Dörsam B., Bösl T., Reiners K.S. et al. Hodgkin lymphoma-derived extracellular vesicles change the secretome of fibroblasts toward a CAF phenotype. Front Immunol 2018;9:1358. doi: 10.3389/fimmu.2018.01358
  17. Hansen H.P., Engels H.M., Dams M. et al. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin’s lymphoma. J Pathol 2014;232(4):405–14. doi: 10.1002/path.4306
  18. Drees E.E.E., Roemer M.G.M., Groenewegen N.J. et al. Extracellular vesicle miRNA predict FDG‐PET status in patients with classical Hodgkin Lymphoma. J Extracell Vesicles 2021;10(9):e12121. doi: 10.1002/jev2.12121
  19. Van Eijndhoven M.A.J., Zijlstra J.M., Groenewegen N.J. et al. Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients. JCI Insight 2016;1(19):e89631. doi: 10.1172/jci.insight.89631
  20. Ueda N., Kato H., Kato S. et al. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure. Hematology 2023;28(1):2207946. doi: 10.1080/16078454.2023.2207946
  21. Veyri M., Spano J.P., Le Bras F. et al. CD30 as a therapeutic target in adult haematological malignancies: Where are we now? Br J Haematol 2023;201(6):1033–46. doi: 10.1111/bjh.18841

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.